Clinical Trial Update: A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 study by GlaxoSmithKline evaluated a targeted immunotherapy against herpes simplex virus, assessing safety, reactogenicity, immune respons…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Genital Herpes
• Herpes Simplex

Drugs mentioned

• HSV-targeted immunotherapy

Snippet

Sponsor: GlaxoSmithKline | Conditions: Herpes Simplex | Phase 1, Phase 2 | Status: COMPLETED